-
Mashup Score: 4
Novartis is acquiring Kate Therapeutics for $1.1 billion, focusing on gene therapy and neuroscience. CEO Vas Narasimhan and CFO Harry Kirsch indicate future M&A deals will likely stay under $3 billion. KateTx’s pipeline includes preclinical candidates for muscular dystrophies, using specialized AAV capsid delivery technology.
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3
Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in unlocking a big, fast-growing market for its blockbuster franchise.
Source: www.bloomberg.comCategories: General Medicine News, General HCPsTweet-
RT @AmberTongPW: Novo Nordisk Launches Wegovy in China With Prices Well Below US https://t.co/uq3Mj7eMXw via @markets
-
-
Mashup Score: 0
Sage’s final hope to turn its business around has failed, leaving the future of the once high-flying company and its postpartum depression drug uncertain.
Source: endpts.comCategories: General Medicine News, General HCPsTweet-
$SAGE takes another hit. From @MaxGelman https://t.co/Pi6NlYNbs7
-
-
Mashup Score: 15
We’ve asked our advisory group in the E100 about how things are shaping up at the FDA and HHS under the new Trump administration and what impact prospective changes could have on the drug development industry. Also, they have insights on the tense China-US relations and drug development, AI and our continuing focus on financing at a critical crossroads for biopharma.
Source: events.endpts.comCategories: General Medicine News, General HCPsTweet-
How's 2025 shaping up in biopharma? That's a really interesting question, so we set up a new executive survey and webinar for it. Register and you get to see me and some industry folk discuss. https://t.co/a6qnneJjoQ
-
-
Mashup Score: 4
In 2010, neuroscientist and former Eli Lilly research leader Steve Paul started a company that he hoped would spark a revolution in drug discovery built around a class of compounds dubbed neurosteroids that could help calm overactive brain circuits and fire up sleepy ones for a long list of psychiatric and neurological conditions.
Source: endpts.comCategories: General Medicine News, General HCPsTweet-
Solid Endpoints in Focus here from @MaxGelman on Sage's "last, best hope." $SAGE once traded at $190. Now under $5. It's a tough business. #biotech https://t.co/sHn16h04oI
-
-
Mashup Score: 8Trump to pick vaccine skeptic Kennedy to lead HHS, in what would be an upheaval of US health policy - 8 day(s) ago
President-elect Donald Trump has picked Robert F. Kennedy Jr. to be his next health secretary, according to reports from CNN and Politico, potentially giving the government’s most powerful healthcare post to a vaccine skeptic whose controversial views would be a huge break with decades of US health and scientific policies.
Source: endpts.comCategories: General Medicine News, General HCPsTweet-
Kennedy to run HHS. Can’t be a surprise at this point. OK, biohive, any thoughts about how this will change things at the FDA and in drug development? https://t.co/fMpQLcsiYL
-
-
Mashup Score: 16
BioNTech is acquiring Chinese biotech Biotheus for $800 million upfront plus $150 million in milestones, gaining multiple clinical-stage drugs, R&D facilities, and 300 employees. The deal centers on BNT327/PM8002, a PD-L1/VEGF bispecific antibody entering registrational trials, and includes manufacturing capabilities in China.
Source: endpts.comCategories: General Medicine News, General HCPsTweet-
Great job by @ky_lahucik on BioNTech's new PD-L1/VEGF acquisition out of China. A great example of #biotech news in context. And interesting to see the PD-1 vs PD-L1 debate continuing in real time. $BNTX $SMMT $MRK https://t.co/jJQYaWSGtU
-
-
Mashup Score: 5
FDA Commissioner Rob Califf discusses his final months in role, addressing potential Trump administration changes, agency performance, and staff retention. He emphasizes importance of expertise, acknowledges executive branch hierarchy in FDA decisions, and notes while FDA traditionally relies on nonpartisan physicians, presidential overrule is legally possible.
Source: endpts.comCategories: General Medicine News, General HCPsTweet-
RT @ZacharyBrennan: ‘Expertise is a real thing’: FDA commissioner warns of political risk to agency https://t.co/0aOX9kyxN5
-
-
Mashup Score: 5
FDA Commissioner Rob Califf discusses his final months in role, addressing potential Trump administration changes, agency performance, and staff retention. He emphasizes importance of expertise, acknowledges executive branch hierarchy in FDA decisions, and notes while FDA traditionally relies on nonpartisan physicians, presidential overrule is legally possible.
Source: endpts.comCategories: General Medicine News, General HCPsTweet-
RT @ZacharyBrennan: ‘Expertise is a real thing’: FDA commissioner warns of political risk to agency https://t.co/0aOX9kyxN5
-
-
Mashup Score: 6Live updates: Trump rapidly rolling out top officials as he prepares for return to White House - 10 day(s) ago
Get the latest news on the transition to the new administration of President-elect Donald Trump and a new Congress.
Source: www.washingtonpost.comCategories: General Medicine News, General HCPsTweet-
Kristi Noem gets Homeland Security -- expect an order to gun down any dogs crossing the border illegally. https://t.co/OouskOj2CU
-
$NVS does some more pipeline tinkering with a $1.1B startup buyout, from @reynaldendpts https://t.co/JsepOoUyNE